Wichtige Publikationen

 

Arbeitsgruppen:

  • Experimental Medicine
  • Pathological mechanisms underlying atherosclerosis
  • Heart Attack Research Team

Experimental Medicine - Wichtigste Publikationen:

  1. Jankowski V, Tölle M, Vanholder R, Schönfelder G, van der Giet M, Henning L, Schlüter H, Paul M, Zidek W, and Jankowski J. Identification of uridine adenosine tetraphosphate (Up4A) as an endothelium-derived vasoconstrictive factor. Nature Medicine 11: 223-227, 2005.
  2. Lautner RQ, Villela DC, Fraga-Silva RA, Silva NC, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, De Sousa FB, Alzamora AC, Soares ER, Barbosa CM, Kjeldsen F, Oliveira AC, Braga JF, Savergnini SQ, Etelvino GM, Bastos Peluso AA, Passos-Silva DG, Ferreira AJ, Alves F, Martins AS, Raizada MK, Paula RD, Motta-Santos D, Klempin F, Pimenta AM, Alenina N, Sinisterra RD, Bader M, Campagnole-Santos MJ, and Santos RA. Discovery and Characterization of Alamandine, a Novel Component of the Renin-Angiotensin System. Circ Res, 2013.
  3. Janke D, Jankowski J, Rueth M, Buschmann I, Lemke H, Jacobi D, Knaus K, Spindler E, Zidek W, Lehmann K, and Jankowski V. The ‘‘artificial artery’’ as in-vitro perfusion model. PLoS One, 2013.
  4. Jankowski V, Tölle M, Santos RA, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, and Jankowski J. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25: 2987-2995, 2011.
  5. Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schlüter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, and Jankowski J. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27: 297-302, 2007.

Pathological mechanisms underlying atherosclerosis - Wichtigste Publikationen:

  1. Noels H*, Zhou B*, Tilstam PV, Theelen W, Li X, Pawig L, Schmitz C, Akhtar S, Simsekyilmaz S, Shagdarsuren E, Schober A, Adams RH, Bernhagen J, Liehn EA, Doring Y, Weber C. Deficiency of endothelial cxcr4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol. 2014;34:1209-1220. *Shared first authorship. |IF(2012): 6.34| PMID 24723559
  2. Doring Y*, Noels H*, Mandl M, Kramp B, Neideck C, Lievens D, Drechsler M, Megens RT, Tilstam PV, Langer M, Hartwig H, Theelen W, Marth JD, Sperandio M, Soehnlein O, Weber C. Deficiency of the sialyltransferase st3gal4 reduces ccl5-mediated myeloid cell recruitment and arrest: Short communication. Circ Res. 2014;114:976-981. *Shared first authorship. |IF(2012): 11.86| PMID 24425712
  3. Zernecke A*, Bidzhekov K*, Noels H*, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microrna-126 by apoptotic bodies induces cxcl12-dependent vascular protection. Sci Signal. 2009;2:ra81. *Shared first authorship. |IF(2012): 7.65 PMID 19996457
  4. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422. |IF(2012): 24.3| PMID 22064431
  5. Döring Y, Pawig L, Weber C*, Noels H*. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol. 2014 Jun 11;5:212. Accepted for publication. *Shared last authorship. No impact factor yet PMID 24966838

Heart Attack Research Team - Wichtigste Publikationen:

  1. Liehn EA, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, Koenen RR, Zander S, Soehnlein O, Hristov M, Grigorescu G, Urs AO, Leabu M, Bucur I, Merx MW, Zernecke A, Ehling J, Gremse F, Lammers T, Kiessling F, Bernhagen J, Schober A, Weber C. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol. 2011;58:2415-23.
  1. Liehn EA, Piccinini AM, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zernecke A, Kungl AJ, Weber C. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol. 2010;56:1847-57.
  1. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C. Nat Med. 2009;15(1):97-103.
  2. Kanzler I, Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A, Simons D, Asare Y, Schober A, Bucala R, Weber C, Bernhagen J, Liehn EA. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol. 2013;108:310.
  1. Oral H, Kanzler I, Tuchscheerer N, Curaj A, Simsekyilmaz S, Sönmez TT, Radu E, Postea O, Weber C, Schuh A, Liehn EA. CXC chemokine KC fails to induce neutrophil infiltration and neoangiogenesis in a mouse model of myocardial infarction. J Mol Cell Cardiol. 2013; 60:1-7.